Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Common Equity (2016 - 2025)

ImmunityBio (IBRX) has disclosed Common Equity for 13 consecutive years, with -$500.5 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 2.32% to -$500.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$500.5 million through Dec 2025, down 2.32% year-over-year, with the annual reading at -$500.5 million for FY2025, 2.32% down from the prior year.
  • Common Equity for Q4 2025 was -$500.5 million at ImmunityBio, up from -$523.4 million in the prior quarter.
  • The five-year high for Common Equity was -$158.6 million in Q2 2021, with the low at -$744.2 million in Q3 2024.
  • Average Common Equity over 5 years is -$469.8 million, with a median of -$494.8 million recorded in 2024.
  • The sharpest move saw Common Equity plummeted 1202.89% in 2021, then grew 29.66% in 2025.
  • Over 5 years, Common Equity stood at -$243.9 million in 2021, then tumbled by 84.42% to -$449.8 million in 2022, then tumbled by 30.26% to -$585.9 million in 2023, then increased by 16.53% to -$489.1 million in 2024, then decreased by 2.32% to -$500.5 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at -$500.5 million, -$523.4 million, and -$569.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.